DiaSorin

Healthcare-associated infections (HAIs) are a major threat to vulnerable hospital patients, affecting more than 1 million patients and resulting in thousands of deaths annually in the US. PCR-based molecular testing of patients suspected of HAIs is key to expediting pathogen detection and patient isolation to prevent potentially deadly HAI outbreaks. Learn more about HAIs in the latest ID Transmission by Dr. Ayaz Majid (Director, Product Mangement - Diasorin): https://hubs.li/Q02YfdQG0 Explore Diasorin’s molecular HAI testing menu: https://hubs.li/Q02YfrKM0 #HAI #Cauris #moleculartesting

Evaluating diabetic status is essential for accurate diagnosis and effective management of diabetes—a condition that impacts millions worldwide. At Diasorin, we are dedicated to advancing the prevention, diagnosis, and management of diabetes. Our mission is to empower patients, families, and healthcare providers with the tools and insights they need to tackle diabetes head-on and enhance quality of life. Together, we’re making strides toward a healthier future. #Diasorin #WorldDiabetesDay

We are continuing to build on our legacy blood culture portfolio with the submission of the LIAISON PLEX® Gram-Positive Blood Culture Assay on the sample-to-answer LIAISON PLEX® System. Gram-positive bacteremia accounts for approximately 60% of all positive blood cultures. Optimized treatment is crucial for saving patients’ lives, and assays built with our proprietary NanoGrid technology have been at the forefront of helping clinicians make critical therapeutic decisions in hours, not days.

Today is World Pneumonia Day, a reminder of the significant impact pneumonia has on global health, with high morbidity, mortality, and associated healthcare costs. To combat this serious infectious disease, Diasorin has been providing specific diagnostic tests for many years. This year, we are proud to introduce the LIAISON® Urinary Ag test, a new automated solution that delivers accurate and rapid results, enhancing our efforts in pneumonia diagnosis and in patient management. #Diasorin #WorldPneumoniaDay

When it comes to treating cCMV, early diagnosis is key. Unfortunately, 91% of women are unaware of the risk of CMV—a common herpes virus that is harmless in most healthy adults. When transmitted during pregnancy, CMV may cause hearing loss and long-term developmental issues in newborns. Early diagnosis is key for #healthymothersandbabies. The Simplexa® Congenital CMV Direct assay is the only FDA-cleared test that detects cCMV in both saliva swabs and confirmatory urine samples in newborns, under 21 days of age, to facilitate the accurate detection and diagnosis of cCMV. For better health in moms and babies, visit our extensive menu of best-in-class diagnostic tests to support women and neonatal health on our website: https://hubs.li/Q02XcB5l0 #cCMV #newbornhealth

Stay updated on what may or may not be covered regarding COVID-19 testing now that the pandemic is over, and COVID-19 is no longer a public health emergency.  Whether your patients are covered under Medicare, Medicaid, or private insurance, or just want to know what safety nets are available for those uninsured, check out our blog summarizing what changes to coverage and reimbursement policies you might expect.  Check out our blog: https://hubs.li/Q02Tqz7S0 #HealthcareReimbursement #Diasorin

It’s no secret that clinical labs are facing a perfect storm of challenges: rising costs, staff shortages, and increased demand. Check out our blog summarizing an interview with two Diasorin team members in Medical Laboratory Observer. Learn what solutions they shared regarding what Diasorin offers for optimizing respiratory testing through the customization of syndromic testing. Read the blog: https://hubs.li/Q02W_Tg70 #Diasorin #LIAISONPLEX

How can pneumonia diagnosis be improved, and what are the main challenges in consistently administering early targeted therapy? These topics will be explored during the webinar “Automated Urinary Antigen Testing in Pneumonia Patient Care” where we will provide background information on the main challenges when diagnosing pneumonia and introduce our new diagnostic approach to better pneumonia diagnosis. Only 3 days left until the webinar. Don’t miss it! Save the date and register: 🔗 https://lnkd.in/dC9w_JSq 

The LIAISON® XL is designed with you in mind. By automating routine tasks and minimizing human error, it frees up your team to focus on what matters most: patient care. With a wider range of premium specialty tests, you can confidently address the growing challenges of infectious diseases, gastrointestinal health, and women's health. Our goal is to empower you to do more with less. Less manual work, less chance of errors, and less stress. More efficient workflows, more accurate results, and more satisfied patients. Are you ready to experience the LIAISON® XL difference? Visit today our page dedicated and contact us to learn more: https://lnkd.in/d9et5sfZ #LIAISONXL #laboratoryefficiency #patientcare #healthcareimprovement #clinicaldiagnostics

Check out our blog to read the highlights of the interview about Diasorin’s solutions for customizable molecular respiratory testing and, the ways labs can streamline their workflows to meet their diagnostic stewardship goals.  At the Association for Diagnostics & Laboratory Medicine, Diasorin team members Michelle Tabb, Chief Scientific Officer, and Giulia Amicarelli, Vice President of Global Molecular Marketing and Marketing Services, offered great insight into the shifting landscape, current challenges, and the latest innovations in respiratory testing in their interview with the Medical Laboratory Observer  Read the blog: https://hubs.li/Q02Tw5px0 #Diasorin #LIAISONPLEX